FIELD: medicine.
SUBSTANCE: substance of the invention consists in administration of 3-oxy-6-methyl-2-ethyl-pyridine succinate (Mexidol) as an agent for reducing toxicity and increasing antineoplastic efficacy of etoposide.
EFFECT: reduced toxicity and increased efficacy of etoposide-containing schedules of antineoplastic chemotherapy ensured by antioxidant action of Mexidol.
5 dwg, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING ONCOLOGICAL DISEASES IN EXPERIMENT | 2007 |
|
RU2396967C2 |
METHOD OF LUNG CANCER TREATMENT | 2008 |
|
RU2365370C1 |
MEDICATION INCREASING ANTITUMOUR EFFECT OF METHOTREXATE | 2009 |
|
RU2411947C1 |
LUNG CANCER THERAPY | 2008 |
|
RU2367436C1 |
SPECIFIC COMBINED THERAPY OF MALIGNANT TUMOURS WITH CYTOSTATIC AGENT AND ITS MODIFYING AGENT | 2015 |
|
RU2571551C1 |
DERIVATIVES OF CARBOXYLIC ACIDS, INHIBITORS OF METASTASIS AND AGENTS ENHANCING CHEMOTHERAPEUTIC ACTIVITY OF ANTITUMOR PREPARATIONS, METHOD FOR ENHANCING EFFECTIVENESS OF CYTOSTATICS, METHOD FOR INHIBITION OF METASTASIZING PROCESS | 2005 |
|
RU2295517C1 |
METHOD FOR TUMOUR GROWTH INHIBITION | 2010 |
|
RU2446844C1 |
METHOD FOR CREATING BIOLOGICAL MODEL OF MODERATE GROWTH INHIBITION OF TUMOUR AND METASTASES IN LEWIS LUNG CARCINOMA WITH PROLONGED CYCLOPHOSPHANINE-INDUCED LEUKOPENIA IN MICE | 2012 |
|
RU2488173C1 |
PHARMACEUTICAL COMPOSITION BASED ON PALLADIUM COMPOUND | 2015 |
|
RU2613305C2 |
PHOSPHOLIPID COMPOSITION OF DOXORUBICIN FOR TREATING PATIENTS WITH BREAST CANCER | 2019 |
|
RU2714137C1 |
Authors
Dates
2011-01-27—Published
2009-04-20—Filed